Core Insights - The article discusses the establishment of a "Technology Assistance for the Disabled Brain-Computer Interface Research Base" in Longgang District, Shenzhen, aimed at advancing brain-computer interface technology for assisting individuals with disabilities [1][2] - A collaborative meeting was held involving Tsinghua University, local healthcare institutions, and the Longgang District Disabled Persons' Federation to outline the development and application of this technology [1] Group 1 - The meeting reached a consensus on five major construction directions for the research base: research base, industrial incubation base, clinical trial base, technology achievement display base, and popular science education base [1] - The team emphasized that Longgang District's practices in technology assistance for the disabled serve as a model for Shenzhen, with plans to deepen collaboration and establish a national benchmark [1] - Participants conducted a site visit to the brain-computer interface platform and rehabilitation facilities at Longgang District's Eighth People's Hospital to explore a collaborative mechanism integrating research, clinical practice, and industry [1] Group 2 - In March 2025, Shenzhen was designated as a key national area for technology assistance for the disabled, with Longgang District actively engaging with universities and enterprises to promote projects like precision medicine for autism and brain-computer interface technology [2] - The Longgang District Disabled Persons' Federation plans to collaborate with Tsinghua University, medical institutions, and high-tech enterprises to accelerate the transformation of technological achievements and explore new avenues in rehabilitation [2]

中办、国办近日发布《关于深入推进深圳综合改革试点深化改革创新扩大开放的意见》，这是深圳改革 开放进程中具有标志性、里程碑意义的大事喜事。深圳社会各界反响强烈，干部群众、专家学者、企业 家投资人兴奋激动，热议深圳迎来又一次的改革红利。 12日，国务院新闻办举行发布会，邀请国家发展改革委、广东省、深圳市以及科技部有关负责人，介绍 《意见》情况并回答媒体关心的问题。部委的解读、省里的支持、深圳的表态、媒体的关切，为《意 见》落地再造舆论氛围，吸引全球目光。 发布会对深圳开展综合改革试点的成果予以充分肯定。 深圳综合改革试点实施近5年来，在重点领域和关键环节率先突破，形成了一批可复制可推广的成熟经 验，已经在全国普遍展开，不少原创性制度成果已被规范上升为国家层面相关制度和政策，为全国进一 步深化改革开放提供了经验资源、发挥了重要的引领示范作用。 发布会对《意见》赋予深圳的新任务进行深度阐述。 在制度型开放、科技创新、人才发展、治理模式等方面开展探索，改革任务具有明显的首创性和引领 性。比如，先行适用国际贸易电子提单、电子信用证等电子单证，探索依托电子提单开展抵押融资等业 务；加强数字人民币试点应用场景创新，探索央行数 ...

【深圳商报讯】（记者詹钰叶）北证专精特新指数拟于6月30日上线，这意味着北交所即将开启"双指 数"时代。北交所最新总市值已超过8000亿元，其中专精特新"小巨人"企业总市值过半。 北交所与中证指数有限公司日前联合发布北证专精特新指数编制方案与样本股名单，拟于6月30日正式 发布实时行情，以反映北交所专精特新企业整体表现，为市场提供多维度投资标的和业绩基准。 根据指数编制方案，此次北证专精特新指数在北交所专精特新"小巨人"企业中选取了50只市值规模和流 动性排名靠前的证券作为指数样本。北交所称，北证专精特新以客观反映北交所专精特新企业运行状况 为目标，同时结合北交所市场现状及专精特新企业特点，对流动性门槛、定期调整等编制要素进行特色 化设置。 同花顺数据显示，截至6月12日，北交所共有267家上市公司，最新总市值为8322.19亿元。其中，专精 特新"小巨人"企业有139家，主要涉及生物医药、高端装备制造、新材料、新一代信息技术等重点领 域，最新总市值为4348.58亿元，占北交所总市值的52.25%；锦波生物、天工股份、曙光数创与星图测 控这4家公司的市值超过100亿元。 西部证券分析师曹森元表示，入选北证专 ...

Core Points - The Shenzhen Housing Construction Bureau has announced the public listing of qualified families for the purchase of talent housing in the Yuyun District, with a total of 1,841 qualified families [1] - A total of 287 units are available for sale, with an average price of 27,800 yuan per square meter [1] - The project is located in Longgang District and consists of two types of units: 164 two-bedroom units (approximately 66 square meters) and 123 three-bedroom units (approximately 85 square meters) [1] Summary by Sections - **Qualified Families**: The list of qualified families for the purchase of talent housing will be publicly available on the Shenzhen Housing Construction Bureau's website until June 18, 2025 [2] - **Application Conditions**: Applicants must meet specific educational and professional qualifications, including having a full-time college degree or equivalent technical qualifications, and single applicants must be at least 30 years old [1][2] - **Contractual Obligations**: Families that have signed agreements for other housing projects will not be included in this batch of qualified applicants, and any changes in marital status must be reported during the public listing period [2]

Group 1 - Company Guanghe Technology (001389) has submitted an application for H-share listing on the Hong Kong Stock Exchange, with a maximum issuance of H-shares not exceeding 20% of the total share capital post-issuance [2] - The funds raised will be used for product research and development, expansion of product applications, capacity expansion, overseas market development, and general corporate purposes [2] - Guanghe Technology is a leading manufacturer of key components for computing servers, focusing on customized PCBs for various applications including computing, industrial, and consumer sectors [2][3] Group 2 - According to Frost & Sullivan, Guanghe Technology ranks first among PCB manufacturers for computing servers in mainland China and third globally, with a market share of 4.9% [3] - The company has shown significant revenue growth, with projected revenues of approximately 24.12 billion yuan, 26.78 billion yuan, and 37.34 billion yuan for 2022, 2023, and 2024 respectively, reflecting year-on-year growth rates of 16.23%, 11.02%, and 39.43% [3] - The net profit attributable to shareholders is expected to reach approximately 2.80 billion yuan, 4.15 billion yuan, and 6.80 billion yuan for the same years, with growth rates of 176.63%, 48.29%, and 63.04% respectively [3]

Core Viewpoint - The launch of the Beijing Stock Exchange (BSE) Specialized and Innovative Index on June 30 marks the beginning of a "dual index" era for the BSE, enhancing its market influence and providing new investment opportunities for investors [1][2]. Group 1: Index Launch and Market Impact - The BSE's total market capitalization has exceeded 800 billion yuan, with specialized and innovative "little giant" enterprises accounting for over half of this value [1][2]. - The new index will include 50 securities selected based on market capitalization and liquidity from the "little giant" enterprises, aiming to objectively reflect their operational status [1][2]. - The introduction of the index is expected to facilitate the development of index ETFs and other investment products, allowing investors to participate more actively in the BSE market [1][2][3]. Group 2: Company Representation and Investment Opportunities - The inclusion of companies in the new index signifies their high market capitalization and representativeness among specialized and innovative enterprises, enhancing their market visibility and brand image [2][3]. - The index is anticipated to guide social resources towards key sectors and strategic emerging industries, promoting innovation and development within these fields [2][3]. - Investors are encouraged to diversify their portfolios based on their risk preferences and investment goals, with the potential for public funds to be developed based on the new index [2][3]. Group 3: Future Outlook and Sector Focus - The BSE's Specialized and Innovative Index reflects its commitment to serving innovative small and medium-sized enterprises, with plans for more industry-specific indices in the future [3]. - Analysts suggest focusing on sectors such as robotics, semiconductor testing, and consumer goods, highlighting specific companies like Suzhou Axle, Audiwei, and Hualing [4].

Core Viewpoint - The Beijing Stock Exchange (BSE) has shown strong performance this year, with related thematic funds experiencing significant net value increases, suggesting medium to long-term investment value in the BSE sector [1][2][3] Group 1: Market Performance - The BSE 50 Index has risen by 37.25% year-to-date, outperforming major indices such as the Shanghai Composite Index and Shenzhen Component Index [1] - Nearly 40 BSE-themed funds have seen an average net value increase of approximately 33.53% this year, with some funds like CITIC Securities BSE Selected Mixed Fund A and Huaxia BSE Innovative SMEs Selected Fund A achieving net value increases of over 70% [1][2] - 24 BSE funds have recorded net value increases exceeding 30% this year, indicating a broad-based positive performance across various funds [2] Group 2: Investment Opportunities - Analysts suggest focusing on companies with growth potential and strong R&D investments, particularly those in hot sectors and those benefiting from capacity expansion [3] - There is an emphasis on companies that are diversifying and expanding their industrial chains, as well as state-owned enterprises with stable operations and strong growth capabilities [3] - Investment strategies include targeting long-cycle performance stability and unique production capabilities, high dividend and steady growth domestic demand stocks, and thematic sectors such as AI and low-altitude economy [3]

Core Viewpoint - Changfeng Pharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange after previous unsuccessful attempts to list on the STAR Market in China, focusing on the development and commercialization of inhalation drugs for respiratory diseases [1][3]. Financial Performance - The company reported revenues of RMB 349.1 million, RMB 556.4 million, and RMB 608 million for the years 2022, 2023, and projected for 2024, respectively, with net profits of -RMB 49.4 million, RMB 31.7 million, and RMB 21.1 million during the same periods [2][4]. - The gross profit margin improved from 76.6% in 2022 to 82.2% in 2023, indicating better cost management [4]. Product Dependency - The company heavily relies on its inhalation product CF017, which accounted for 96.2%, 98.4%, and 94.5% of total revenue in 2022, 2023, and projected for 2024, respectively [4][6]. - CF017 is the company's first approved product for treating bronchial asthma, highlighting the risk of revenue concentration [4][6]. Sales and Distribution - Approximately 98.8%, 99.5%, and 99.3% of the company's product sales revenue came from distributors during the reporting periods, indicating a strong dependence on the distribution network [7]. - The company has a high customer concentration, with revenue from the top five customers accounting for 60.2%, 69.4%, and 66.4% of total revenue in the respective years [8]. Cost Structure - Sales and distribution expenses have increased over the reporting periods, totaling approximately RMB 594 million over three years [9]. - Research and development expenses were RMB 1.07 billion, RMB 1.33 billion, and RMB 1.22 billion for the years 2022, 2023, and projected for 2024, with a noted decrease in 2024 due to outsourcing certain services [9].

深圳商报·读创客户端记者 靳恩琦 6月11日，Cloudbreak Pharma Inc.（以下简称"拨康视云"）再次于港交所递交招股书，联席保荐人为建银国际及华泰国际。 据悉，这已经是该公司第四次在港交所递表，该公司曾于2023年11月、2024年5月、2024年12月2日向港交所提交过上市申请书。 | 面値 每股股份0.0001美 [編纂] | | --- | | . 股份代號 | 招股书显示，拨康视云是一间临床阶段眼科生物科技公司，致力于开发各种疗法。眼科是研究眼部结构、功能和疾病的医学分支。公司首家主要营运实体 Cloudbreak USA于2015年9月在美国注册成立及公司于2020年11月在开曼群岛注册成立。 拨康视云拥有两款核心产品（CBT-001及CBT-009），均为自主开发。核心产品CBT-001适用于治疗翼状胬肉（一种良性增生性眼表疾病），已分别于2022 年6月及2023年9月在美国及中国启动第3期多地区临床试验。核心产品CBT-009用于治疗青少年近视（5至19岁儿童及青少年近视），于2023年1月完成第1/2 期临床试验，并于2024年7月向美国食品及药物管理局提交新药临床试验申请 ...

Group 1 - The core point of the news is that Honghe Technology announced a planned share acquisition by Hefei Ruicheng Private Equity Fund, a subsidiary of Chery Group, for approximately 1.575 billion yuan, which will result in Ruicheng Fund holding 25% of the company's total shares and becoming the indirect controlling shareholder [1] - Following the announcement, Honghe Technology's stock price hit the daily limit up after resuming trading on June 11 [1] - The transaction is part of a broader trend where private equity funds are encouraged by regulatory authorities to acquire listed companies to promote industry consolidation [1] Group 2 - Ruicheng Fund is controlled by Chery Capital, which is fully owned by Chery Holdings Group and Chery Automobile [2] - The main business of Ruicheng Fund includes private equity investment fund management and venture capital fund management [2] - The entry of private equity funds into listed companies is seen as a win-win situation, as these funds can provide valuable industry resources and professional integration capabilities to optimize the business structure of the listed companies [2]